• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

nicholas.hardcastle@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-7796-8472

Dr Nicholas Hardcastle

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

273 Scholarly works
5 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Standardization of breast radiotherapy structure nomenclature using transformer-based multi-modal feature learning
    DOI: 10.1016/j.bspc.2026.110906
  • 2026

    Journal article

    Version upgrades in treatment planning Systems affect clinical application of a multi-Centre knowledge-based planning model
    DOI: 10.1016/j.tipsro.2026.100417
  • 2026

    Research grants (other domestic)

    Evaluating the Effect of Radiotherapy on the Musculoskeletal Growth of Paediatric Patients Using Anatomical Mapping Models
  • 2026

    Journal article

    Radiation Therapy Target Objectives for Tonsillar Cancer Treated With Unilateral Radiation Therapy—A Replanning Study From TROG 12.01
    DOI: 10.1016/j.ijrobp.2025.12.058
  • 2026

    Journal article

    Stereotactic Ablative Radiotherapy (SABR) one stop service for lung cancer: A pilot study for early-stage Non-Small-Cell Lung Cancer (NSCLC)
    DOI: 10.1016/j.radonc.2026.111553
  • 2024

    Research grants (other domestic)

    Next-Generation Radiotherapy Treatment Planning With Artificial Intelligence
  • 2022

    Research grants (other domestic)

    Sitting Up for Radiotherapy
Nicholas Hardcastle

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Correction: Benna-Doyle et al. Investigating the Prognostic Value of Pretreatment Body Composition in Women with Ovarian Cancer: Impact on Clinical Outcomes. Cancers 2026, 18, 1478.
    DOI: 10.3390/cancers18132055
  • 2026

    Journal article

    Special Issue on Sustainability
    DOI: 10.1111/1754-9485.70136
  • 2026

    Journal article

    Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
    DOI: 10.1016/S1470-2045(26)00170-1
  • 2026

    Journal article

    Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
    DOI: 10.1016/S1470-2045(26)00091-4
  • 2026

    Journal article

    Lymph Node Sampling Patterns and Completeness of Staging During Systematic Mediastinal Lymph Node Staging in Patients with Locally Advanced Non-Small-Cell Lung Cancer: A Post Hoc Analysis from the SEISMIC Study
    DOI: 10.3390/cancers18111766
  • 2026

    Journal article

    Deep learning and radiomics models in patients with advanced non-small cell lung cancer treated with immunotherapy combined with stereotactic radiotherapy.
    DOI: 10.1038/s41598-026-53520-5

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer
  • 2024

    Research grants (other domestic)

    Stereotactic Ablative Body Radiotherapy (SABR) for 4 Gynaecologic Metastases

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224